MADRID (Reuters) – the pharmaceutical Almirall said on Monday that its net profit fell a 29 cent to 84.2 million euros, while operating (ebitda) gross profit fell 26% to 160,1 EUR million.
Seven analysts in a Reuters survey expected average a net result of 89.1 million and an ebitda of 165.3 million.
In its press release, Almirall said its 2011 results were in line with its own forecasts in an environment complicated.
In a note to clients, Banesto Bolsa described as bad, but already discounted results to be in line with the “guidance” of the company and the market more awaiting approval of products such as the bronchodilator Aclidinium and Linaclotida, a drug for the treatment of irritable bowel syndrome.
Laboratory will explain the annual accounts to analysts in a conference call to the 1000 local time, with the focus on the recent favourable opinion of a Committee of experts to use aclidinio bromide in the treatment of COPD in United States.
